||15:00 - 16:15
This symposium focusses on non-surgical treatment options for a broad range of corneal and ocular surfaces pathologies. Hence, pathophysiology and state-of-the-art therapeutic concepts will be presented. These will cover ocular surface dryness, GvHD, reports from the first application of NGF in humans. Furthermore, latest therapeutic strategies relating to (lymph-)angiogenesis and to enhancement/protection of corneal endothelial cells will be discussed.
|Dry eye disease: Is there a way to stop it?||Sa16-01 |
David A Sullivan
Dry eye disease impacts hundreds of millions of people throughout the world and is one of the most common causes of patient visits to eye care practitioners. Dry eye is characterized by a vicious cycle of tear film instability and hyperosmolarity, which leads to increased ocular surface inflammation, damage, neurosensory abnormalities and pain. I will give a brief overview of dry eye pathophysiology and then focus on a new potential treatment for this disease.
|Interdisciplinary drug therapy in chronic ocular GvHD||Sa16-02 |
|NGF: First application in humans||Sa16-03 |
|New options for antiangiogenesis at the cornea and ocular surface||Sa16-04 |
New options for antiangiogenesis at the cornea and ocular surface are discussed with a special focus on corneal transplantation in the high-risk scenario and clinical trial data.
|New concepts for the treatment of diseased corneal endothelium||Sa16-05 |
This presentation presents non-surgical approaches to enhance endothelial cell density using various agents and drug delivery tools.